The association among leukocyte apoptosis, autoantibodies and disease severity in systemic lupus erythematosus

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Su, Yu Jih ^a,c   Cheng, Tien Tsai ^a   Chen, Chung Jen ^a   Chiu, Wen Chan ^a   Hsu, Chung Yuan ^a   Chang, Wen Neng ^b   Tsai, Nai Wen ^b   Kung, Chia Te ^a   Wang, Hung Chen ^a   Lin, Wei Che ^a   Huang, Chih Cheng ^b   Chang, Ya Ting ^b   Su, Chih Min ^a,c   Chiang, Yi Fang ^b   Cheng, Ben Chung ^a,c   Lin, Yu Jun ^a,c   Lu, Cheng Hsien ^b,c  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

Autoantibodies; Diseases severity score; Leukocyte apoptosis; Systemic lupus erythematosus

Indexed keywords

7 AMINODACTINOMYCIN; AUTOANTIBODY; CD19 ANTIGEN; CELL PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; LA ANTIBODY; LIPOCORTIN 5; MI 2 ANTIBODY; PROTEIN APO2.7; RO52 ANTIBODY; RO60 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKOCYTE; MALE; MONOCYTE; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; APOPTOSIS; AUTOANTIBODIES; CASE-CONTROL STUDIES; FEMALE; HUMANS; LEUKOCYTES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME;

EID: 84885500301     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-261     Document Type: Article

References (35)

1. Hanly JG, et al. Comparison between multiplex assays for autoantibody detection in systemic lupus erythematosus. J Immunol Meth 2010, 358(1-2):75-80.
2. Hassan AB, et al. Serial analysis of Ro/SSA and La/SSB antibody levels and correlation with clinical disease activity in patients with systemic lupus erythematosus. Scand J Rheumatol 2002, 31(3):133-139.
3. Smith EL, Shmerling RH. The American college of rheumatology criteria for the classification of systemic lupus erythematosus: strengths, weaknesses, and opportunities for improvement. Lupus 1999, 8(8):586-595. 10.1191/096120399680411317, 10568894.
4. Jin O, et al. Lymphocyte apoptosis and macrophage function: correlation with disease activity in systemic lupus erythematosus. Clin Rheumatol 2005, 24(2):107-110. 10.1007/s10067-004-0972-x, 15818511.
5. van Bavel CC, et al. Apoptosis-induced histone H3 methylation is targeted by autoantibodies in systemic lupus erythematosus. Ann Rheum Dis 2011, 70(1):201-207. 10.1136/ard.2010.129320, 20699234.
6. Cohen PL, et al. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med 2002, 196(1):135-140. 10.1084/jem.20012094, 2194017, 12093878.
7. Navratil JS, Ahearn JM. Apoptosis, clearance mechanisms, and the development of systemic lupus erythematosus. Curr Rheumatol Rep 2001, 3(3):191-198. 10.1007/s11926-001-0018-1, 11352787.
8. Huggins ML, et al. Antibodies from systemic lupus erythematosus (SLE) sera define differential release of autoantigens from cell lines undergoing apoptosis. Clin Exp Immunol 1999, 118(2):322-328. 10.1046/j.1365-2249.1999.01063.x, 1905419, 10540198.
9. Robak E, et al. Peripheral blood lymphocyte apoptosis and circulating dendritic cells in patients with systemic lupus erythematosus: correlation with immunological status and disease-related symptoms. Clin Rheumatol 2006, 25(2):225-233. 10.1007/s10067-005-1163-0, 16432661.
10. Xie M, et al. [Preliminary study on apoptosis and expression of apoptosis-related genes in peripheral blood lymphocytes of patients with systemic lupus erythematosus]. Hua Xi Yi Ke Da Xue Xue Bao 1999, 30(2):192-195.
11. Bombardier C, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992, 35(6):630-640. 10.1002/art.1780350606, 1599520.
12. Fox RI, et al. Sjogren's syndrome. Proposed criteria for classification. Arthritis Rheum 1986, 29(5):577-585. 10.1002/art.1780290501, 3718551.
13. Wallace DJ, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009, 61(9):1168-1178. 10.1002/art.24699, 2758229, 19714604.
14. Koester SK, et al. Monitoring early cellular responses in apoptosis is aided by the mitochondrial membrane protein-specific monoclonal antibody APO2.7. Cytometry 1997, 29(4):306-312. 10.1002/(SICI)1097-0320(19971201)29:4<306::AID-CYTO7>3.0.CO;2-7, 9415413.
15. Carthy CM, et al. Early release of mitochondrial cytochrome c and expression of mitochondrial epitope 7A6 with a porphyrin-derived photosensitizer: Bcl-2 and Bcl-xL overexpression do not prevent early mitochondrial events but still depress caspase activity. Lab Invest 1999, 79(8):953-965.
16. Soruri A, et al. Mycobacterial antigens induce apoptosis in human purified protein derivative-specific alphabeta T lymphocytes in a concentration-dependent manner. Immunology 2002, 105(2):222-230. 10.1046/j.0019-2805.2001.01355.x, 1782647, 11872098.
17. Belot A, et al. Protein kinase C delta deficiency causes mendelian systemic lupus erythematosus with B-cell defective apoptosis and hyperproliferation. Arthritis Rheum 2013, 65:2161-2171. 10.1002/art.38008, 23666743.
18. Dhir V, et al. Increased T-lymphocyte apoptosis in lupus correlates with disease activity and may be responsible for reduced T-cell frequency: a cross-sectional and longitudinal study. Lupus 2009, 18(9):785-791. 10.1177/0961203309103152, 19578102.
19. Caricchio R, Cohen PL. Spontaneous and induced apoptosis in systemic lupus erythematosus: multiple assays fail to reveal consistent abnormalities. Cell Immunol 1999, 198(1):54-60. 10.1006/cimm.1999.1576, 10612651.
20. Liu C, et al. Effects of sex hormones on apoptosis in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Chin Med J (Engl) 2001, 114(3):291-293.
21. Bengtsson AA, et al. Induction of apoptosis in monocytes and lymphocytes by serum from patients with systemic lupus erythematosus - an additional mechanism to increased autoantigen load?. Clin Exp Immunol 2004, 135(3):535-543. 10.1111/j.1365-2249.2003.02386.x, 1808958, 15008990.
22. Armstrong DJ, et al. Distinctive effects of G-CSF, GM-CSF and TNFalpha on neutrophil apoptosis in systemic lupus erythematosus. Clin Exp Rheumatol 2005, 23(2):152-158.
23. Chen W, Lin J. Lymphopenia relating to T-lymphocyte apoptosis in systemic lupus erythematosus. Clin Rheumatol 2011, 30(11):1515-1516. 10.1007/s10067-011-1852-9, 21927798.
24. Munoz LE, et al. Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus 2008, 17(5):371-375. 10.1177/0961203308089990, 18490410.
25. Manson JJ, Isenberg DA. The origin and pathogenic consequences of anti-dsDNA antibodies in systemic lupus erythematosus. Expert Rev Clin Immunol 2006, 2(3):377-385. 10.1586/1744666X.2.3.377, 20476909.
26. Dillon CF, Jones JV, Reichlin M. Antibody to Ro in a population of patients with systemic lupus erythematosus: distribution, clinical and serological associations. J Rheumatol 1983, 10(3):380-386.
27. Villarreal GM, et al. Prevalence of 13 autoantibodies and of the 16/6 and related pathogenic idiotypes in 465 patients with systemic lupus erythematosus and their relationship with disease activity. Lupus 1997, 6(5):425-435. 10.1177/096120339700600503, 9229360.
28. Carthy CM, et al. Bcl-2 and Bcl-xL overexpression inhibits cytochrome c release, activation of multiple caspases, and virus release following coxsackievirus B3 infection. Virology 2003, 313(1):147-157. 10.1016/S0042-6822(03)00242-3, 12951029.
29. Pan Y, et al. [Effects of glucocorticoids on the expression of GTIR and apoptosis of the CD4(+)CD25(+)CD127(dim/-) T cells in patients with systemic lupus erythematosus]. Beijing Da Xue Xue Bao 2012, 44(2):215-220.
30. Bohm I. Apoptosis: the link between autoantibodies and leuko-/lymphocytopenia in patients with lupus erythematosus. Scand J Rheumatol 2004, 33(6):409-416. 10.1080/03009740410006907, 15794201.
31. Linker-Israeli M, Quismorio FP, Horwitz DA. CD8+ lymphocytes from patients with systemic lupus erythematosus sustain, rather than suppress, spontaneous polyclonal IgG production and synergize with CD4+ cells to support autoantibody synthesis. Arthritis Rheum 1990, 33(8):1216-1225.
32. Midgley A, et al. The role of neutrophil apoptosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2009, 60(8):2390-2401. 10.1002/art.24634, 19644848.
33. Habib HM, et al. Enhanced propensity of T lymphocytes in patients with systemic lupus erythematosus to apoptosis in the presence of tumour necrosis factor alpha. Scand J Rheumatol 2009, 38(2):112-120. 10.1080/03009740802409496, 19110660.
34. Balanescu E, et al. Immunohistochemical aspects of apoptosis in subcutaneous lupus erythematosus. Rom J Intern Med 2010, 48(3):261-265.
35. Makino H, et al. Glomerular cell apoptosis in human lupus nephritis. Virchows Arch 2003, 443(1):67-77. 10.1007/s00428-003-0827-x, 12750884.